Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://nanafebf542357.worldblogged.com/49230568/novo-nordisk-s-retatrutide-australia-a-potential-hope-for-obesity-treatment